{
    "clinical_study": {
        "@rank": "122729", 
        "arm_group": [
            {
                "arm_group_label": "Placebo capsules", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsules"
            }, 
            {
                "arm_group_label": "AMP-886 (alpha-tocotrienol) in capsules", 
                "arm_group_type": "Experimental", 
                "description": "AMP-886 (alpha-tocotrienol) in capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to investigate the effect of AMP886 (alpha-tocotrienol) on health\n      status and quality of life measures, cognitive functioning, oxidative stress, inflammation\n      markers and other symptoms effects on skin, sleep and vision in the elderly."
        }, 
        "brief_title": "Health Status and Quality of Life in the Elderly", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Quality of Life", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females 65-85 years old\n\n          -  ECOG Performance score 0 to 1\n\n          -  Body mass index 22-30 kg/m2\n\n          -  Body weight >60 kg\n\n          -  Habit to consume standard breakfast like toast, bread, butter/margarine, eggs, bacon,\n             cereals with milk\n\n          -  Comply with protocol and likely to be compliant with prescribed product\n\n        Exclusion Criteria:\n\n          -  Renal insufficiency or failure at screening\n\n          -  Current or previous positive documented history of any chronic inflammatory state\n             including chronic infection, arthritis, or collagen vascular disorder.\n\n          -  Comorbid medical conditions\n\n          -  Use of prescription medication for chronic conditions\n\n          -  Use of hormone replacement therapy (with the exception of levothyroxine)\n\n          -  Uncontrolled hypertension\n\n          -  Use of hemostatic agents\n\n          -  Hemorrhagic disorder and/or coagulation disorder\n\n          -  Clinically important bleeding within 90 days prior to screening visit\n\n          -  Fat malabsorption syndromes\n\n          -  Constipation and/or abdominal pain/discomfort that require dietary supplements or\n             medical therapy\n\n          -  History of smoking within 1 year prior to visit 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953172", 
            "org_study_id": "FDS-NBU-1034"
        }, 
        "intervention": [
            {
                "arm_group_label": "AMP-886 (alpha-tocotrienol) in capsules", 
                "description": "AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules", 
                "intervention_name": "AMP-886", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "alpha-tocotrienol"
            }, 
            {
                "arm_group_label": "Placebo capsules", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tocotrienol, alpha", 
                "Vitamin E", 
                "Tocotrienols", 
                "Tocopherols"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "King's College Hospital"
                }, 
                "investigator": {
                    "last_name": "S Jackson, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "E11 1NR"
                    }, 
                    "name": "Whipps Cross Hospital"
                }, 
                "investigator": {
                    "last_name": "A Bewley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M13 9WL"
                    }, 
                    "name": "Central Manchester Hospital"
                }, 
                "investigator": {
                    "last_name": "J Lear, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Exploratory, Double-blind, Randomized, Placebo Controlled Study of AMP-886 in the Elderly", 
        "overall_contact": {
            "email": "carole.verhoeven@unilever.com", 
            "last_name": "C Verhoeven, PhD", 
            "phone": "+31 10 4605441"
        }, 
        "overall_official": {
            "affiliation": "Unilever Research and Development", 
            "last_name": "C Verhoeven, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Objective of this exploratory study is to evaluate the effects of AMP886 on health status", 
                "measure": "Effects on health status and quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Objective of this exploratory study is to evaluate the effects of AMP886 on quality of life measures", 
                "measure": "Effects on health status and quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Objective of this exploratory study is to evaluate the effects of AMP886 on cognitive functioning", 
                "measure": "Effects on health status and quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Objective of this exploratory study is to evaluate the effects of AMP886 on  oxidative stress", 
                "measure": "Effects on health status and quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Objective of this exploratory study is to evaluate the effects of AMP886 on  inflammation markers", 
                "measure": "Effects on health status and quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Objective of this exploratory study is to evaluate the effects of AMP886 on  skin", 
                "measure": "Effects on health status and quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Objective of this exploratory study is to evaluate the effects of AMP886 on  vision", 
                "measure": "Effects on health status and quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953172"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Unilever R&D", 
        "sponsors": {
            "collaborator": {
                "agency": "Sprim Advanced Life Sciences", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Unilever R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}